S100A9 and metabolic dysfunction-associated steatohepatitis: But, in NASH patients with fibrosis, the level of S100A8, S100A9, and S100A8/A9 is significantly increased in comparison with controls P = 0.008, P = 0.0168, and P = 0.0001, respectively (Figures 2(a), 2(b), and 2(c)).